The benefits, costs and feasibility of a low incidence COVID-19 strategy. (2022)
Attributed to:
Biomedicine and Beyond: The Social and Regulatory Dimensions of Therapeutics in Japan and the UK
funded by
FIC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.lanepe.2021.100294
PubMed Identifier: 35005678
Publication URI: http://europepmc.org/abstract/MED/35005678
Type: Journal Article/Review
Volume: 13
Parent Publication: The Lancet regional health. Europe
ISSN: 2666-7762